A Bayesian approach for population pharmacokinetic modelling of sirolimus

British Journal of Clinical Pharmacology

Volumn 62, Issue 4, 2006, Pages 420-434

  Dansirikul, Chantaratsamon ^a,c   Morris, Raymond G ^b   Tett, Susan E ^a   Duffull, Stephen B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEEN ELIZABETH HOSPITAL   (Australia)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Bayesian population modelling; Population pharmacokinetic analysis; Prior elicitation; Sirolimus; WinBUGS

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

ACCURACY; ADULT; AGE; AGED; ARTICLE; BAYES THEOREM; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; KIDNEY GRAFT; MALE; MATHEMATICAL MODEL; POPULATION PHARMACOKINETIC MODEL; PRIORITY JOURNAL; PROBABILITY; RECIPIENT; STEADY STATE;

ADULT; BAYES THEOREM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MODELS, BIOLOGICAL; SIROLIMUS; TREATMENT REFUSAL;

EID: 33748750319     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02533.x     Document Type: Article

References (38)

1. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl B): B101-21.
2. Kahan BD, Napoli KL, Podbielski J, Hussein I, Katz SH, Van Buren CT. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes. Transplant Proc 2001; 33: 1278.
3. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330-50; discussion 329.
4. Yatscoff RW, Boeckx R, Holt DW, Kahan BD, LeGatt DF, Sehgal S, Soldin SJ, Napoli K, Stiller C. Consensus guidelines for therapeutic drug monitoring of rapamycin: report of the consensus panel. Ther Drug Monit 1995; 17: 676-80.
5. Zimmerman JJ, Kahan BD. Pharmacokinetics of sirolimus in stable renal transplant patients after multiple oral dose administration. J Clin Pharmacol 1997; 37: 405-15.
6. Kumi KA. Approval package for 021083: Clinical pharmacology and biopharmaceutics review(s). http://www.fda.gov/cder/foi/nda/99/ 21083A_Rapamune_clinphrmr.pdf.
7. Zimmerman JJ, Ferron GM, Lim HK, Parker V. The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin). J Clin Pharmacol 1999; 39: 1155-61.
8. Brattstrom C, Sawe J, Jansson B, Lonnebo A, Nordin J, Zimmerman JJ, Burke JT, Groth CG. Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. Ther Drug Monit 2000; 22: 537-44.
9. Bottiger Y, Sawe J, Brattstrom C, Tollemar J, Burke JT, Hass G, Zimmerman JJ. Pharmacokinetic interaction between single oral doses of diltiazem and sirolimus in healthy volunteers. Clin Pharmacol Ther 2001; 69: 32-40.
10. Yatscoff RW. Pharmacokinetics of rapamycin. Transplant Proc 1996; 28: 970-3.
11. Brattstrom C, Sawe J, Tyden G, Herlenius G, Claesson K, Zimmerman J, Groth CG. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997; 19: 397-406.
12. Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61: 416-28.
13. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 2003; 9: 130-7.
14. Staatz CE, Willis C, Taylor PJ, Tett SE. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002; 72: 660-9.
15. Bruno R, Vivler N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm 1996; 24: 153-72.
16. Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn 2002; 29: 473-505.
17. Wakefield J, Bennett J. The Bayesian modeling of covariates for population pharmacokinetic models. J Am Stat Assoc 1996; 91: 917-27.
18. Gillespie WR, Khoo KC. Population pharmacokinetics in pediatric patients using Bayesian approaches with informative prior distributions based on adults. [Abstract PI-93]. Clin Pharmacol Ther 1999; 65: 140.
19. Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA. An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 2001; 48: 887-93.
20. Wade JR, Kelman AW, Howie CA, Whiting B. Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis. J Pharmacokinet Biopharm 1993; 21: 209-22.
21. Chaloner K, Church T, Louis TA, Matts JP. Graphical elicitation of a prior distribution for a clinical trial. Statistician 1993; 42: 341-53.
22. Tan SB, Chung YF, Tai BC, Cheung YB, Machin D. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Control Clin Trials 2003; 24: 110-21.
23. French DC, Saltzgueber M, Hicks DR, Cowper AL, Holt DW. HPLC assay with ultraviolet detection for therapeutic drug monitoring of sirolimus. Clin Chem 2001; 47: 1316-9.
24. Sirolimus international proficiency testing scheme. Analytical Services International Ltd, http://www.bioanalytics.co.uk.
25. Dansirikul C, Choi M, Duffull SB. Estimation of pharmacokinetic parameters from non-compartmental variables using Microsoft Excel (R). Comput Biol Med 2005; 35: 389-403.
26. Bland JM, Kerry SM. Statistics notes. Weighted comparison of means. BMJ 1998; 316: 129.
27. Duffull SB, Kirkpatrick CMJ, Green B, Holford NHG. Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat 2005; 15: 53-73.
28. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: General concepts and software. J Pharmacokinet Pharmacodyn 2002; 29: 271-307.
29. Lunn DJ, Wakefield J, Thomas A, Best NG, Spiegelhalter DJ. Pkbugs User Guide, Version 1.1. London: Imperial College 1999.
30. Kass RE, Carlin BP, Gelman A, Neal RM. Markov chain Monte Carlo in practice: a roundtable discussion. Am Stat 1998; 52: 93-100.
31. Friberg LE, Dansirikul C, Duffull SB. Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis [abstract]. Population Approach Group in Europe (PAGE). Uppsala, Sweden, 2004.
32. Gelman A. Bayesian Data Analysis, 2nd edn. Boca Raton, Fla, Chapman & Hall/CRC, 2004.
33. Friberg LE, Isbister GK, Hackett LP, Duffull SB. The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. J Pharmacokinet Pharmacodyn 2005; in press.
34. Mu S, Ludden TM. Estimation of population pharmacokinetic parameters in the presence of non-compliance. J Pharmacokinet Pharmacodyn 2003; 30: 53-81.
35. Dansirikul C, Staatz CE, Duffull SB, Taylor PJ, Lynch SV, Tett SE. Sampling times for monitoring tacrolimus in stable adult liver transplant recipients. Ther Drug Monit 2004; 26: 593-9.
36. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 2005; 77: 76-89.
37. Altman DG, Smith GD, Egger M. Systematic Reviews in Health Care: Meta-Analysis in Context, 2nd edn. London, British Medical Journal, 2001.
38. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.